Kevin Bitterman Sells 22,160 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 22,160 shares of Disc Medicine stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $77.23, for a total value of $1,711,416.80. Following the sale, the director owned 478,461 shares in the company, valued at $36,951,543.03. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Bitterman also recently made the following trade(s):

• On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00.
• On Thursday, October 16th, Kevin Bitterman sold 1,425 shares of Disc Medicine stock. The stock was sold at an average price of $77.11, for a total transaction of $109,881.75.
• On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The stock was sold at an average price of $70.58, for a total transaction of $5,079,007.38.
• On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The shares were sold at an average price of $68.38, for a total transaction of $1,233,506.82.
• On Friday, August 22nd, Kevin Bitterman sold 2,287 shares of Disc Medicine stock. The stock was sold at an average price of $61.03, for a total value of $139,575.61.
• On Thursday, August 14th, Kevin Bitterman sold 7,212 shares of Disc Medicine stock. The shares were sold at an average price of $60.99, for a total value of $439,859.88.
• On Wednesday, August 13th, Kevin Bitterman sold 24,962 shares of Disc Medicine stock. The stock was sold at an average price of $61.15, for a total value of $1,526,426.30.
• On Tuesday, August 5th, Kevin Bitterman sold 395 shares of Disc Medicine stock. The shares were sold at an average price of $60.95, for a total value of $24,075.25.
• On Wednesday, July 30th, Kevin Bitterman sold 8,492 shares of Disc Medicine stock. The shares were sold at an average price of $61.04, for a total transaction of $518,351.68.
• On Thursday, July 24th, Kevin Bitterman sold 13,033 shares of Disc Medicine stock. The stock was sold at an average price of $61.17, for a total transaction of $797,228.61.

Disc Medicine Trading Up 21.0%

Shares of NASDAQ IRON opened at $89.94 on Friday. The firm’s 50 day moving average price is $63.69 and its 200-day moving average price is $54.76. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $95.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.11 and a current ratio of 32.11. The company has a market cap of $3.13 billion, a PE ratio of -20.12 and a beta of 0.80.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.41). On average, equities research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Wedbush raised their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a report on Friday. National Bankshares set a $153.00 target price on shares of Disc Medicine in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a report on Thursday, July 3rd. Finally, Cantor Fitzgerald lifted their price objective on Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $108.73.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IRON. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after acquiring an additional 181 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the period. Amalgamated Bank increased its stake in shares of Disc Medicine by 38.6% in the first quarter. Amalgamated Bank now owns 787 shares of the company’s stock worth $39,000 after purchasing an additional 219 shares in the last quarter. HighVista Strategies LLC raised its position in shares of Disc Medicine by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 6,733 shares of the company’s stock valued at $357,000 after purchasing an additional 275 shares during the period. Finally, Avanza Fonder AB lifted its stake in shares of Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after buying an additional 585 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.